Literature DB >> 3415215

Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults.

F Borsa1, A Leroy, J P Fillastre, M Godin, B Moulin.   

Abstract

The pharmacokinetics of two oral forms of fosfomycin, tromethamine (trometamol) salt and calcium salt, were studied in five young (age, 29 +/- 3 [standard deviation] years) and eight elderly (age, 72 +/- 6 years) adults. The subjects received a single 40-mg/kg (body weight) (approximately equal to 3-g) calcium fosfomycin dose and a 25-mg/kg (approximately equal to 2-g) tromethamine fosfomycin dose in fosfomycin acid form. Blood and urine samples were collected for 24 h. Antibiotic concentrations in serum and urine were measured by microbiological assay. In all subjects, the peak levels of the calcium salt in serum were two- to fourfold lower than those of the tromethamine salt (6 to 7 and 18 to 22 micrograms/ml, respectively), indicating poor intestinal absorption of the calcium form. The elimination half-life of the two oral forms was about 5 h in young adults, and the half-life was only moderately longer in elderly subjects, with large individual variations: 8.28 +/- 5.51 h for tromethamine fosfomycin and 11.80 +/- 6.86 h for calcium fosfomycin. In elderly subjects, absorption of the tromethamine salt form was not modified, but the time to peak level was delayed for the calcium salt (2.58 +/- 0.54 h versus 1.41 +/- 0.67 h in young adults). Pharmacokinetic elimination of the two forms of fosfomycin was only moderately affected in elderly subjects; we observed lower urinary elimination, about 58 versus 28% of the dose in 24-h urines for the tromethamine salt and decreased renal clearance of both forms. However, the dosages of tromethamine and calcium fosfomycin need not be adjusted for elderly subjects who have endogenous creatinine clearances above 50 ml/min per 1.73 m2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415215      PMCID: PMC172313          DOI: 10.1128/AAC.32.6.938

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Factors influencing the activity of the trometamol salt of fosfomycin.

Authors:  D Greenwood; A Jones; A Eley
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Fosfomycin: Absorption and excretion.

Authors:  K Shimizu
Journal:  Chemotherapy       Date:  1977       Impact factor: 2.544

3.  Pharmacokinetic profile of fosfomycin trometamol (Monuril).

Authors:  G Segre; E Bianchi; A Cataldi; G Zannini
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

4.  Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction.

Authors:  E Bergogne-Bérézin; C Muller-Serieys; M L Joly-Guillou; N Dronne
Journal:  Eur Urol       Date:  1987       Impact factor: 20.096

5.  Oral glucose tolerance and insulin response after one week's clonidine treatment in hypertensive patients.

Authors:  C Barbieri; R Caldara; G Testori; V Piepoli; R Trezzi; M Romussi; C Ferrari
Journal:  Acta Diabetol Lat       Date:  1981

6.  Fosfomycin kinetics after intravenous and oral administration to human volunteers.

Authors:  M Goto; M Sugiyama; S Nakajima; H Yamashina
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

  6 in total
  18 in total

1.  Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Authors:  E Wenzler; E J Ellis-Grosse; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 3.  Plasmid-encoded fosfomycin resistance.

Authors:  J E Suárez; M C Mendoza
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 4.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

5.  Susceptibility testing quality control studies with fosfomycin tromethamine.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

Review 6.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

Review 7.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

8.  In vitro susceptibility testing procedures for fosfomycin tromethamine.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine.

Authors:  A L Barry; M A Pfaller; P C Fuchs; F C Tenover; L B Reller; S D Allen; D J Hardy; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

10.  Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

Authors:  T Bergan
Journal:  Infection       Date:  1990       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.